Glucagon is believed to be a pancreas-specific hormone and hyperglucagonemia has been shown to contribute significantly to the hyperglycemic state of patients with diabetes. This hyperglucagonemia has been thought to arise from alpha cell insensitivity to suppressive effects of glucose and insulin combined with reduced insulin secretion. We hypothesized that postabsorptive hyperglucagonemia represents a gut-dependent phenomenon and subjected 10 totally pancreatectomized patients and 10 healthy controls to a 75g-oral glucose tolerance test and a corresponding isoglycemic intravenous glucose infusion. We applied novel analytical methods of plasma glucagon (sandwich enzyme-linked immunosorbent assay and mass-spectrometry-based proteomics) and show that 29-amino acid glucagon circulates in patients without a pancreas and that glucose stimulation of the gastrointestinal tract elicits significant hyperglucagonemia in these patients. These findings emphasize the existence of extrapancreatic glucagon (perhaps originating from the gut) in man and suggest that it may play a role in diabetes secondary to total pancreatectomy.
Abstract
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Patients with diabetes are characterized not only by compromised insulin secretion and action, but also by elevated plasma concentrations of the 29-amino acid peptide hormone glucagon, which hitherto has been considered a pancreas-derived hormone in humans (produced in and secreted from alpha cells in the islet of Langerhans) (1) . In patients with diabetes, plasma concentrations of glucagon are elevated in the fasting state and fail to decrease appropriately or even increase in response to an oral glucose tolerance test (OGTT) and show exaggerated increases in response to ingestion of a mixed meal (1, 2) . The elevated glucagon concentrations increase the hepatic glucose production and thereby contribute significantly to the fasting and postprandial hyperglycemia characterizing patients with diabetes. The etiology behind diabetic hyperglucagonemia is still controversial. While oral intake of glucose elicits a hyperglucagonemic response, intravenous glucose administration causes suppression of plasma glucagon levels (3, 4) . A 'lighter version' of this phenomenon has also been observed in healthy individuals after ingestion of larger oral glucose loads (4) .
Together, these findings led us to speculate that postprandial hyperglucagonemia could be gut-derived and independent of the endocrine pancreas.
The notion of extrapancreatic glucagon secretion in man has been debated for years, and several studies looking at glucagon responses following total pancreatectomy in animals (5-10) and man (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) have been published. Overall, these investigations have reported very conflicting results. One of the main challenges is that many of the glucagon assays suffer from shortcomings, and until recently, analytical methods have not been sufficiently sensitive or specific to justify decisive statements about the absence or presence of extrapancreatic fully processed 29-amino acid glucagon (24). Recently, however, sandwich enzyme-linked immunosorbent assays (ELISAs) using a combination of C and N-terminal anti-glucagon antibodies, and thus, in theory eliminating cross-reactivity with elongated or truncated forms of glucagon, have become available (25). Furthermore, technical advances have made it possible to detect low-abundant peptides, such as glucagon, in human plasma by mass-spectrometry-based proteomics (26, 27) . Applying these novel techniques, we aimed to investigate whether postabsorptive hyperglucagonemia occurs independently of functioning pancreatic islets and plasma glucose and insulin concentrations by measuring plasma concentrations of 29-amino acid glucagon in totally pancreatectomized patients and healthy control subjects following 75 g-OGTT and isoglycemic intravenous glucose infusion (IIGI).
Research Design and Methods

Study Design
This study examined glucagon responses in totally pancreatectomized patients and healthy control subjects during OGTT and IIGI. The study was conducted at the Center for Diabetes Research (Gentofte Hospital, Hellerup, Denmark), was approved by the Ethics Committee of the Capital Region of Denmark (reg. no. H-1-2012-123), and conducted in accordance to the principles of the Helsinki Declaration (Seventh revision, 2013).
Study Participants
Ten totally pancreatectomized patients (age [mean ± SD]: 59.8 ± 9.9 years; BMI: 21.5 ± 4.3 kg/m 2 ; HbA 1c : 67.3 ± 11.0 mmol/mol; time since operation: 4.6 ± 4.5 years), and 10 age, sex and BMI-matched healthy control subjects (age: 58.4 ± 5.0 years; BMI: 22.9 ± 2.4 kg/m 2 ;
HbA 1c : 34.6 ± 6.2 mmol/mol) without any family history of diabetes were studied. Clinical characteristics of the totally pancreatectomized subjects are displayed in Table 1 and a schematic illustration of the anatomy before and after surgery (28) is depicted in Fig. 1 .
Experimental procedures
After an initial screening visit, participants were examined on two study days separated by at least 72 hours. Subjects were studied after an overnight (10 hours) fast and patients were instructed to take their normal daily insulin doses the day before but not to take any insulin on the morning of the experimental day. On the first day a 75 g-OGTT was performed.
Participants were placed in a recumbent position and cannulas were inserted in cubital veins, one for infusion of stable isotopes and one in the contra-lateral vein for collection of arterialized blood with the hand wrapped in a heating pad (~50°C 
Calculations and Statistical Analysis
Area under the curves (AUCs) were calculated using the trapezoidal rule. Gastrointestinalmediated glucose disposal (GIGD) was calculated from the amount of glucose ingested during the OGTT related to the amount administered during the IIGI using the formula: 
Results
Plasma Glucose
Following the 75 g-OGTT, a mean peak concentration of 27.9 ± 1.4 mmol/l was reached at time point 150 min in the totally pancreatectomized patients compared to a mean peak concentration of 9.1 ± 0.5 mmol/l at time point 60 min in the healthy control subjects ( Fig.   2A ). The individually adjustable intravenous glucose infusions resulted in glucose excursions over time similar to those during the corresponding OGTT (isoglycemia) in both the pancreatectomy group and the control group ( Fig. 2A and Table 2 ). The total amount of glucose infused during the IIGI, copying the plasma glucose excursions from the 75 g-OGTT, amounted to 28.5 ± 1.8 g in the control group and 83.3 ± 3.1 g in the pancreatectomy group (142 ± 9 and 416 ± 19 ml of 20% w/v glucose solution, respectively, P < 0.001), corresponding to a GIGD of 62.0 ± 2.4% in the control group and -11.0 ± 5.0%, in the pancreatectomy group (P < 0.001) -both different from 0% (P < 0.001 and P = 0.05, respectively).
C-peptide and PP
C-peptide and PP concentrations in the totally pancreatectomized patients were below detection limit of the assays (< 16 pmol/l and < 0.5 pmol/l, respectively) at all time points on both days ( 
Glucagon
In the totally pancreatectomized patients basal concentrations of glucagon were above detection limit (1 pmol/l) of the applied sandwich ELISA (P < 0.001) with levels tending to be lower compared to the healthy control subjects although without reaching statistical significance ( Fig. 3A and Table 2 ). Following OGTT, the totally pancreatectomized patients responded with significant secretion of glucagon resulting in mean peak levels of 18.8 ± 3.0 pmol/l (at time point 30 min) whereas immediate suppression of glucagon concentrations was seen after initiation of the intravenous glucose infusion ( Fig. 3A and B) . The healthy control subjects responded with significant suppression of glucagon concentrations on both the OGTT day and the IIGI day, but glucagon suppression following oral glucose was delayed compared to during intravenous glucose infusion -in line with previous observations (4, 33) . To verify that the observed glucagon responses in the pancreatectomy group were in fact due to the presence of 29-amino acid glucagon we performed affinity chromatography ( 
Glucose and Glycerol Kinetics
Baseline levels of glucose rate of appearance (R a ) and rate of disappearance (R d ) were higher in the totally pancreatectomized patients compared to the healthy control subjects (P < 0.001, for both measures) ( Fig. 4A and B) . In the pancreatectomy group, R d of glucose was higher during IIGI compared to OGTT (P = 0.005) driven partly by a higher glucose excretion in the urine during the IIGI (15.6 ± 2.9 vs. 12.3 ± 2.3 g, P = 0.01). R a of glucose over time was also higher during IIGI compared to OGTT in the pancreatectomy group (P = 0.02). Baseline levels of endogenous R a of glucose were higher in the totally pancreatectomized patients compared to the healthy control subjects (P < 0.001) and not different between study days in each group (Fig. 4C ). Suppression of endogenous R a was enhanced during IIGI compared to OGTT in both groups reflecting a mean difference
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between the two days in endogenous glucose production (EGP) over 3 hours of 16.5 ± 2.3 g in the pancreatectomy group and 6.0 g ± 1.0 g in the control group (P = 0.001). Basal concentrations of plasma glycerol were higher in the totally pancreatectomized patients compared to the healthy control subjects (146 ± 22 vs. 80 ± 13 µmol/l, P = 0.022), but within each group, no difference in responses over time between study days was observed (Fig. 4D ). Plasma glycerol concentrations in the control group were significantly reduced (to ~50% of baseline levels) following both OGTT and IIGI whereas no significant changes over time were seen in the pancreatectomy group. Mean levels of R a and R d , respectively, for glycerol ( Fig. 4E and F) were higher in the pancreatectomy group compared to the control group likely explained by the insulin-deficient state of the patients.
Gastrin and CCK
The control group responded with significant secretion of gastrin following OGTT while no change from baseline was observed during IIGI ( Fig. 5A and Table 2 ). In the pancreatectomy group no differences in gastrin concentrations were observed over time neither during OGTT or IIGI (P = NS). However, total AUC (but not baseline-subtracted AUC) was greater during OGTT compared to IIGI. Gastrin responses over time during
OGTT were greater in the control group compared to the pancreatectomy group (P = 0.01).
Significantly higher responses of CCK were observed in both groups during OGTT compared to IIGI (Fig. 5B and Table 2 ). However, no significant differences in CCK responses over time were observed between the pancreatectomy group and the control group during OGTT (P = 0.13).
Incretin Hormones
Basal concentrations of GIP were similar on the two study days in each group, but tended to be higher in the totally pancreatectomized patients compared to the healthy control subjects ( Fig. 5C and Table 2 ). During OGTT, significant GIP responses were observed in both groups with no significant differences between the two groups. Basal concentrations of GLP-1 (from enteroendocrine L cells) were significantly higher in the pancreatectomy group compared to the control group ( Fig. 4D and Table 2 ). GLP-1 responses during OGTT were larger in the pancreatectomy group compared to the control group (P < 0.001) with a threefold higher peak value at time point 30 min (92 ± 18 vs. 30 ± 5 pmol/l, P = 0.008).
GIP(1-30)
Basal concentrations of GIP(1-30), argued to be a product of prohormone convertase (PC)2 processing of proGIP in pancreatic alpha cells and therefore not secreted from the enteroendocrine K cells from where the major isoform GIP(1-42) is secreted (34) were similar between study days in each group and not different between groups (Table 2 ).
Responses over time were similar between days in both the pancreatectomy group and the control group (P = 0.59 and P = 0.49, respectively) and likewise no differences in responses over time were observed between groups during OGTT (P = 0.09) (Fig. 5E ).
Oxyntomodulin
Basal concentrations of the enteroendocrine L cell product oxyntomodulin were significantly higher in the pancreatectomy group compared to the control group ( Fig. 5F and Table 2 ). AUC during OGTT was significantly higher in the pancreatectomy group compared to the control group driven by the higher basal concentrations as baseline-subtracted AUCs were not different (Table 2) . No significant changes from baseline occurred during IIGI in either group.
Discussion
This study demonstrates that 29-amino acid glucagon is circulating in man after total pancreatectomy and that glucagon secretion in these patients is stimulated by orally administered glucose and suppressed when glucose is administered intravenously.
Furthermore, our data suggest that the hyperglucagonemic response to OGTT in totally pancreatectomized patients is involved in the pathogenesis of postabsorptive hyperglycemia as EGP was markedly higher during OGTT compared to during intravenously administered glucose where glucagon values were suppressed. In the present study, we used a recently developed sandwich ELISA targeting the N-and Cterminal regions of glucagon simultaneously whereby these specificity problems should be eliminated (25). In order to verify the accuracy of this assay we analyzed plasma from totally pancreatectomized patients for glucagon by employing a mass-spectrometry-based We found an increased EGP during OGTT compared to during IIGI in the totally pancreatectomized patients, which might be a consequence of the postprandial hyperglucagonemia. The pancreatectomized patients had a higher R d of glucose during the IIGI day compared to the OGTT day despite isoglycemic conditions and no difference in insulin treatment on the two experimental days. But this difference in R d was driven primarily by a difference in glucosuria between the two days; most likely explained by the larger volume of liquid infused during IIGI compared to the volume ingested during OGTT.
Interestingly, a higher rate of EGP was also observed in the healthy control subjects during OGTT compared to IIGI (albeit the difference was considerably smaller than in the pancreatectomy group). This finding might seem counterintuitive, as significantly more insulin was secreted during the OGTT compared to the IIGI. The explanation could be that maximum insulin-mediated suppression of EGP in the healthy individuals was reached already with the insulin levels obtained during IIGI, combined with stimulatory effects from the delayed suppression of glucagon observed during OGTT in these subjects. The higher R a and R d of glycerol and, thus, the higher lipolysis-rate in the pancreatectomy group compared to the control group is likely explained by the insulin-deficient state of the patients. 
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The Tables   Table 1   Clinical Creon (pancreas enzyme replacement therapy): 40,000: 25,000 EP-e amylase, 40,000 EP-e lipase and 1,600 EP-e protease; Creon 25,000: 18,000 EP-e amylase, 25,000 EP-e lipase and 1,000 EP-e protease; Creon 10,000: 8,000 EP-e amylase, 10,000 EP-e lipase and 600 EP-e protease; IU, international unit subsequently pooled and subjected to tandem mass spectrometry-based proteomic (E).
Peptide intensities (log 2 -transformed) are color-coded from low (green) to high (red) concentration with a false discovery rate of less than 1%. The 29-amino acid sequence corresponding to that of glucagon is depicted in bold font. Data are mean ± SEM. Statistical analysis was done by linear mixed effect modeling for analysis of repeated measures between days within groups, and two-sample Student´s t test (two-tailed), paired or unpaired, were used for analysis of bsAUC. Asterisks (*) indicate significant (P < 0.05) differences.
Figure 4
The rate of glucose appearance (R a ) (A), rate of glucose disappearance (R d ) (B), endogenous R a of glucose (C), concentrations of plasma glycerol (D), rate of glycerol appearance (R a ) (E) and rate of glycerol disappearance (R d ) (F) during a 75 g-oral glucose tolerance test (OGTT) and isoglycemic intravenous glucose infusion (IIGI), respectively, in totally pancreatectomized patients (PX) (n = 10) and healthy control subjects (CTRL) (n = 10).
Data are mean ± SEM. Statistical analysis was done by linear mixed effect modeling for analysis of repeated measures between days within groups. Asterisks (*) indicate significant (P < 0.05) differences. Na. Fractions were analyzed using a C-terminal specific glucagon radioimmunoassay as described previously (3, 4) . For preparation of samples for mass spectrometry analysis, plasma was pooled (from the 10 totally pancreatectomized subjects before and during OGTT) and purified using pH resistant tc18 cartridges as described previously (5) . One thousand µl of reconstituted samples was subjected to reversed phase HPLC (Akta purifier, Amersham
Biosciences, Vydac, SC, USA). Effluent samples were collected automatically in 500 µl portions and lyophilized. Pellets were resuspended in digestion buffer containing either LysC, trypsin, chymotrypsin, respectively and as well urea/thiourea and 50 mmol/l ammonium bicarbonate buffer pH 7.5) and desalted on stage tips (6). For LC-MS/MS analysis, the samples were first applied to a Thermo Scientific EASY-nLC 1000 HPLC system (Thermo Fisher Scientific, Odense, Denmark). Columns (75 µm inner diameter, 20 cm length) were inhouse-packed with 1.9 µm C18 particles (Dr. Maisch GmbH, Entringen, Germany). Peptides were loaded in buffer A (0.5% formic acid) and separated with a gradient from 10 to 60%
